1. NPATA represents the statutory net profit after tax before impairment and amortisation of acquired IP, business acquisition and integration costs and the unwind of the inventory fair value uplift associated with the acquisition of Vifor Pharma. Independent Audit of the Report The Remuneration Report for the year ended 30 June 2024 (Report) has been audited by Deloitte Touche Tohmatsu (Deloitte). Please see page 153 of the Financial Statements for Deloitte’s report. 1. 2024 CSL KMP This Report sets out remuneration information for CSL’s KMP which includes NEDs, the Executive Director (i.e., the CEO) and the key senior executives who had authority and responsibility for planning, directing and controlling the activities of CSL during the financial year (together with the Executive Director, referred to as Executive KMP). CSL’s KMP during the financial year ended 30 June 2024 (2024) and changes to KMP are outlined in Table 1. On 30 June 2023, Mr Andrew Schmeltz joined CSL in the newly created position of EVP CSL Behring. Mr Schmeltz became KMP effective 1 September 2023, when he fully transitioned into his role and responsibilities. Mr Bruce Brook retired from the Board on 11 October 2023, after serving four terms as a NED. Ms Samantha Lewis joined the CSL Board of Directors on 1 January 2024. Table 1: CSL KMP in 2024 Name Position Term as KMP NEDs Dr Brian McNamee AO Chair and Independent Non-Executive Director Full year Dr Megan Clark AC Independent Non‑Executive Director Full year Professor Andrew Cuthbertson AO Non-Independent Non‑Executive Director Full year Ms Carolyn Hewson AO Independent Non-Executive Director Full year Ms Samantha Lewis Independent Non-Executive Director Part year – from 1 January 2024 Professor Duncan Maskell Independent Non-Executive Director Full year Ms Marie McDonald Independent Non-Executive Director Full year Ms Alison Watkins AM Independent Non-Executive Director Full year Former NEDs Mr Bruce Brook Independent Non-Executive Director Part year – until 11 October 2023 Executive KMP Dr Paul McKenzie Executive Director and CEO Full year Ms Joy Linton Chief Financial Officer Full year Mr Andrew Schmeltz EVP CSL Behring Part year – from 1 September 2023 Contents 1. 2024 CSL KMP 2. 2024 Executive KMP Remuneration at a Glance 3. 2024 Global Remuneration Framework 4. Five Year CSL Financial Performance and Executive KMP Reward Outcomes 5. Executive KMP Outcomes in 2024 6. Remuneration in 2025 7. Remuneration Governance 8. NED Remuneration 9. KMP Statutory Tables 10. Additional Employee Equity Programs and Legacy Plan Information Abbreviations AGM Annual General Meeting ARMC Audit and Risk Management Committee CEO Chief Executive Officer and Managing Director CFO Cashflow from Operations EPS Earnings per Share EPSg Earnings per Share growth EVP Executive Vice President FR Fixed Reward HRRC Human Resources and Remuneration Committee KMP Key Management Personnel KPI Key Performance Indicator LTI Long Term Incentive NED Non-Executive Director NPATA Net Profit after Tax and before Amortisation1 PSU Performance Share Unit ROIC Return on Invested Capital RSU Restricted Share Unit STI Short Term Incentive TDC Total Target Direct Compensation US United States of America 79
RkJQdWJsaXNoZXIy MjE2NDg3